rosepsis and Intra abdominal Sepsis
Not Applicable
- Conditions
- Health Condition 1: - Health Condition 2: N37- Urethral disorders in diseases classified elsewhere
- Registration Number
- CTRI/2024/05/066803
- Lead Sponsor
- Pfizer PHARMACEUTICALS
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
WERE CONSECUTIVELY ADMITTED TO THE HOSPITAL BETWEEN 01 APRIL 2020 AND 31 MARCH 2023
HAD SUSPECTED OR DOCUMENTED MDR GRAM NEGATIVE INTRA ABDOMINAL SEPSIS OR UROSEPSIS
SEPSIS WAS DIAGNOSED ACCORDING TO THE THIRD INTERNATIONAL CONSENSUS DEFINITION FOR SEPSIS AND SEPTIC SHOCK
RECIEVED CEFTAZIDIME AVIBACTUM FOR ATLEAST 48 HOURS AS PER CLINICIAN DISCRETIO
Exclusion Criteria
DOCUMENTED ACINETOBACTER INFECTION
RECIEVED CEFTADIZIME AVIBACTUM LESS THAN 48 HOURS
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method IN PATIENT MORTALITY <br/ ><br>CLINICAL OUTCOMES MEASURED ON DAY 3 AND DAY 14 /END OF TREATMENT FROM THE INITIATIONOF CEFTAZIDIME AVIBACTUM TREATMENT.Timepoint: IN PATIENT MORTALITY <br/ ><br>CLINICAL OUTCOMES MEASURED ON DAY 3 AND DAY 14 /END OF TREATMENT FROM THE INITIATIONOF CEFTAZIDIME AVIBACTUM TREATMENT.
- Secondary Outcome Measures
Name Time Method 14 DAYS ALL CAUSE MORTALITY <br/ ><br>MICROBIOLOGICAL OUTCOMES <br/ ><br>30 DAYS ALL CAUSE MORTALITY <br/ ><br>RECURRENCE OF INFECTION <br/ ><br>SAFETY <br/ ><br>LENGTH OF HOSPITAL STAY <br/ ><br>LENGTH OF ICU STAY <br/ ><br>DY OF CEFTAZIDIME AVIBACTUM INITIATION AVERAGE DOSE AND DURATION <br/ ><br>CLINICAL OUTCOMES IN PATIENTS INITIATED WITH CEFTAZIDIME AVIBACTUMWITHIN 48 TO 72 HOURS FROM DIAGNOSIS OF INFECTION <br/ ><br>DISTRIBUTION OF PATHOGENS AND SUSCEPTIBILITY TO CEFTAZIDIME AVIBACTUM IF AVAILABLE <br/ ><br>GENOTYPING RESULTS IF AVAILABLE <br/ ><br>CONCOMITANT ANTIBIOTIC MEDICATIONS WITH CEFTAZIDIME AVIBACTUMTimepoint: 14 TO 30 DAYS